培湧 廖

Dr. 培湧 廖

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2016 in BMC Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
PHPo-Chi Hsu
Po-Chi Hsu
YHYu-Chuen Huang
Yu-Chuen Huang
JCJohn Y. Chiang
John Y. Chiang
HCHen-Hong Chang
Hen-Hong Chang
培廖培湧 廖
培湧 廖
LLLun-Chien Lo
Lun-Chien Lo
Diabetes mellitus (DM) is a hypercoagulable state and is associated with highly increased risk of vascular complications. In the theory of traditional Chinese medicine (TCM), these vascular complications are classified as blood stasis. Diagnosis of the tongue plays an important role in TCM; a bluish tongue, petechiae, and engorged sublingual collateral vessels are manifestations of blood stasis. This study aimed to characterize the tongue manifestations of blood stasis and derive a relationship between blood stasis and vascular disorders in patients with type 2 DM. We conducted a cross-sectional study of 140 patients with type 2 DM, and compared demography, laboratory, physical examination, ankle brachial index(ABI), brachial-ankle pulse wave velocity (ba-PWV), and tongue manifestation datas. An automatic tongue diagnosis system was used to capture tongue images and characterize clinical tongue manifestations. A bluish or petechiae tongue was assoicated with a significant decrease in high-density lipoprotein level, and bluish tongue was associated with significant increase in blood triglyceride in patients with type 2 DM. On assessing arterial stiffness, patients with a petechiae tongue had a higher ba-PWV for both sides (L:1938.41 ± 469.54 cm/sec v.s.1723.99 ± 302.16, p = 0.02; R:1937.28 ± 405.55 v.s.1741.99 ± 325.82, p = 0.03). Blood stasis, particularly a tongue with petechiae, may be associated with arterial stiffness in patients with type 2 DM. Furthermore, tongue diagnosis could detect blood stasis relevant to DM and could serve as a feasible predictor for DM.

25 May 2023 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
THTin-Yun Ho
Tin-Yun Ho
HLHsin-Yi Lo
Hsin-Yi Lo
GLGuan Ling Lu
Guan Ling Lu
培廖培湧 廖
培湧 廖
CHChien-Yun Hsiang
Chien-Yun Hsiang

17 November 2023 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
CHChien-Yun Hsiang
Chien-Yun Hsiang
HLHsin-Yi Lo
Hsin-Yi Lo
GLGuan Ling Lu
Guan Ling Lu
培廖培湧 廖
培湧 廖
THTin-Yun Ho
Tin-Yun Ho

17 November 2023 in American Journal of Gastroenterology
Verified
Journal Article
Open access
THTsung-Hui Hu
Tsung-Hui Hu
DLDih-Ling Luh
Dih-Ling Luh
YTYo-Yu Tsao
Yo-Yu Tsao
TLTing-Yu Lin
Ting-Yu Lin
CCChun-Ju Chang
Chun-Ju Chang
OFOn Behalf Of The Changhua Hepatitis C Elimination Task Force
On Behalf Of The Changhua Hepatitis C Elimination Task Force
INTRODUCTION: Despite the serious risks of diabetes with hepatitis C virus (HCV) infection, this preventable comorbidity is rarely a priority for HCV elimination. We aim to examine how a shared care model could eliminate HCV in patients with diabetes (PwD) in primary care. METHODS: There were 27 community-based Diabetes Health Promotion Institutes in each township/city of Changhua, Taiwan. PwD from these institutes from January 2018 to December 2020 were enrolled. HCV screening and treatment were integrated into diabetes structured care through collaboration between diabetes care and HCV care teams. Outcome measures included HCV care continuum indicators. Township/city variation in HCV infection prevalence and care cascades were also examined. RESULTS: Of the 10,684 eligible PwD, 9,984 (93.4%) underwent HCV screening, revealing a 6.18% (n = 617) anti-HCV seroprevalence. Among the 597 eligible seropositive individuals, 507 (84.9%) completed the RNA test, obtaining 71.8% positives. Treatment was initiated by 327 (89.8%) of 364 viremic patients, and 315 (86.5%) completed it, resulting in a final cure rate of 79.4% (n = 289). Overall, with the introduction of antivirals in this cohort, the prevalence of viremic HCV infection dropped from 4.44% to 1.34%, yielding a 69.70% (95% credible interval 63.64%–77.03%) absolute reduction. DISCUSSION: Although HCV prevalence varied, the care cascades achieved consistent results across townships/cities. We have further successfully implemented the model in county-wide hospital-based diabetes clinics, eventually treating 89.6% of the total PwD. A collaborative effort between diabetes care and HCV elimination enhanced the testing and treatment in PwD through an innovative shared care model.

Verified
Journal Article
Open access
PDF file
PHPo-Chi Hsu
Po-Chi Hsu
培廖培湧 廖
培湧 廖
TYTse-Yen Yang
Tse-Yen Yang
HCHen-Hong Chang
Hen-Hong Chang
JCJohn Y. Chiang
John Y. Chiang
DLDer-Yen Lee
Der-Yen Lee
Diagnosis and monitoring of type 2 diabetes mellitus (T2DM) typically rely on invasive blood-based biomarkers. To explore non-invasive alternatives, this study examined tongue coating metabolites to identify metabolic signatures linked to diabetes progression. A case-control observational study categorized participants into control, prediabetes, and diabetes groups. Tongue coating samples were analyzed using liquid chromatography-mass spectrometry (LC-MS). Differential metabolites were correlated with clinical parameters, including HbA1c, BMI, and eGFR. Distinct metabolic profiles emerged across groups, with significant differences in five endogenous metabolites (phenylpyruvic acid, propionylcarnitine, pyridoxal 5′-phosphate, phenethylamine, phenethylamine glucuronide) and four amino acids (isoleucine, lysine, phenylalanine, tyrosine). Diabetic subjects showed elevated phenylpyruvic acid and phenethylamine, while propionylcarnitine, pyridoxal 5′-phosphate, and phenethylamine glucuronide were reduced. Phenethylamine was positively correlated with HbA1c; propionylcarnitine and phenethylamine glucuronide showed negative correlations with HbA1c and BMI. Detected total amino acids were inversely correlated with eGFR. Additionally, a diabetes index derived from these metabolic features also holds potential for discriminating disease states. These findings underscore the potential of tongue coating metabolites as a relatively non-invasive approach for evaluating T2DM states. The observed metabolic alterations provide valuable insights into diabetes-associated dysregulation, including protein glycation, obesity-related metabolic shifts, and renal impairment.

13 August 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
培廖培湧 廖
培湧 廖
HYHsin-Ting Yu
Hsin-Ting Yu
TYTse-Yen Yang
Tse-Yen Yang
HLHsin-Yi Lo
Hsin-Yi Lo
CHChien-Yun Hsiang
Chien-Yun Hsiang
THTin-Yun Ho
Tin-Yun Ho
Background/Objectives: Interactions between botanical supplements and standard antidiabetic therapies remain poorly understood. This study investigated the efficacy and mechanistic properties of a bitter melon blood-sugar-modulating protein (BMP) in relation to concurrent metformin use for improving glucose and lipid metabolism. Methods: A translational approach combined mechanistic evaluation in db/db mice with an exploratory, real-world observational cohort study of 119 individuals with prediabetes or diabetes. BMP was characterized by liquid chromatography-electrospray ionization-tandem mass spectrometry. In the retrospective self-controlled clinical arm, participants receiving daily BMP supplementation were stratified by metformin use and dosage to evaluate changes in glycated hemoglobin (HbA1c) and lipid profiles over 3 months. Results: In db/db mice, BMP significantly reduced fasting blood glucose and HbA1c, with greater glucose-lowering efficacy observed when combined with metformin compared to metformin alone (approximately 300 mg/dL vs. 200 mg/dL reduction; p < 0.05). Skeletal muscle transcriptomic analysis identified coordinated regulation of 27 shared pathways involved in glucose and lipid metabolism. In the clinical cohort, BMP supplementation was associated with reductions in HbA1c (−0.23%, p = 0.0028), total cholesterol (−7.5 mg/dL), and low-density lipoprotein cholesterol (−6.1 mg/dL) among metformin users, whereas no significant changes were observed in non-users. The greatest observed HbA1c reduction (−0.32%, p < 0.0001) occurred in participants receiving 1000 mg/day of metformin. Conclusions: Preclinical data demonstrate coordinated pathway remodeling in skeletal muscle and improved glycemic control when BMP is combined with metformin. In the clinical cohort, BMP supplementation was associated with modest reductions in HbA1c and lipid parameters, primarily among participants using concurrent metformin. Given the retrospective, self-controlled design and baseline clinical differences between treatment groups, these clinical findings reflect observational associations rather than causal effects. Overall, this study is the first to demonstrate that BMP, a major protein component of bitter melon, exhibits complementary metabolic effects when combined with first-line antidiabetic therapy in animal models. Furthermore, by revealing a corresponding observational association in human clinical settings, this work establishes an important foundation for nutritional protein research.